Related Experiment Video
Updated: Jul 30, 2026
06:28
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
Obesity drugs and the heart
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Current Problems in Cardiology
|December 28, 1999
Summary
Fenfluramine and dexfenfluramine exposure may cause pulmonary hypertension and valvular heart disease. Long-term cardiovascular effects and prognosis require further study to understand the full public health impact.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Appetite suppressant medications, including fenfluramine and dexfenfluramine, have been linked to pulmonary hypertension and valvular heart disease.
- Millions worldwide have been exposed to these drugs, necessitating an understanding of potential cardiovascular risks.
Purpose of the Study:
- To investigate the underlying mechanisms of appetite suppressant-related cardiovascular disorders.
- To evaluate the clinical significance and long-term prognosis of cardiovascular effects in exposed individuals.
- To determine the potential public health impact of these drug-induced conditions.
Main Methods:
- The study emphasizes the need for longitudinal research to track cardiovascular outcomes.
- Analysis of existing data on fenfluramine and dexfenfluramine exposure.
- Review of reported cases of disease regression after drug cessation.
Main Results:
- The precise mechanisms driving these cardiovascular disorders remain uncertain.
- The long-term prognosis and clinical significance of cardiovascular effects are not yet established.
- The natural history of these conditions, including potential for regression, is not fully understood.
Conclusions:
- Further longitudinal studies are crucial to elucidate the disease processes and long-term consequences.
- Understanding the full public health implications requires more data on cardiovascular outcomes.
- The natural history of appetite suppressant-induced pulmonary hypertension and valvular heart disease warrants continued investigation.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...